City Holding Co. Sells 3,630 Shares of DaVita Inc. $DVA

City Holding Co. decreased its position in shares of DaVita Inc. (NYSE:DVA) by 83.4% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 720 shares of the company’s stock after selling 3,630 shares during the quarter. City Holding Co.’s holdings in DaVita were worth $82,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of DVA. Elevation Wealth Partners LLC boosted its stake in shares of DaVita by 147.3% in the fourth quarter. Elevation Wealth Partners LLC now owns 277 shares of the company’s stock worth $31,000 after acquiring an additional 165 shares during the period. Canada Pension Plan Investment Board purchased a new position in DaVita in the 2nd quarter worth approximately $43,000. iSAM Funds UK Ltd purchased a new position in DaVita in the 3rd quarter worth approximately $46,000. Stance Capital LLC bought a new position in DaVita in the 3rd quarter worth approximately $47,000. Finally, SJS Investment Consulting Inc. grew its holdings in DaVita by 3,091.7% during the 3rd quarter. SJS Investment Consulting Inc. now owns 383 shares of the company’s stock valued at $51,000 after buying an additional 371 shares in the last quarter. Hedge funds and other institutional investors own 90.12% of the company’s stock.

DaVita Trading Down 0.1%

Shares of NYSE:DVA opened at $149.89 on Monday. The company has a 50-day moving average price of $148.90 and a 200 day moving average price of $129.41. DaVita Inc. has a 12 month low of $101.00 and a 12 month high of $159.42. The company has a market cap of $10.01 billion, a price-to-earnings ratio of 15.13, a PEG ratio of 0.52 and a beta of 0.92.

DaVita (NYSE:DVA) last issued its quarterly earnings data on Monday, February 2nd. The company reported $3.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.24 by $0.16. The business had revenue of $3.62 billion for the quarter, compared to the consensus estimate of $3.51 billion. DaVita had a negative return on equity of 413.18% and a net margin of 5.47%.The company’s quarterly revenue was up 9.9% compared to the same quarter last year. During the same period in the prior year, the business posted $2.24 earnings per share. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. As a group, equities analysts forecast that DaVita Inc. will post 10.76 EPS for the current year.

Analyst Ratings Changes

DVA has been the topic of several recent analyst reports. TD Cowen reiterated a “hold” rating on shares of DaVita in a research report on Tuesday, February 3rd. Zacks Research downgraded shares of DaVita from a “strong-buy” rating to a “hold” rating in a report on Monday, April 6th. Weiss Ratings reiterated a “hold (c)” rating on shares of DaVita in a research note on Monday, December 29th. Truist Financial set a $158.00 price objective on shares of DaVita in a report on Thursday, February 5th. Finally, Barclays raised their price objective on DaVita from $143.00 to $158.00 and gave the company an “equal weight” rating in a research report on Tuesday, February 3rd. One equities research analyst has rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, DaVita has an average rating of “Hold” and an average price target of $155.80.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.